A DNA alkylating agent
Related Products
Active Metabolite(s)
27171N-desmethyl Bendamustine
Labeled Version(s)
31316Bendamustine-d4 (hydrochloride)
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Bendamustine (hydrochloride)

Item No. 23693

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid, monohydrochloride
CAS Number
3543-75-7
Synonyms
  • SDX-105
Molecular Formula
C16H21Cl2N3O2 • HCl
Formula Weight
394.7
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMSO: >50 mg/mlEthanol: >10 mg/mlMethanol: >50 mg/mlWater: >10 mg/ml
λmax
235, 329 nm
SMILES
ClCCN(CCCl)C1=CC=C(N(C)C(CCCC(O)=O)=N2)C2=C1.Cl
InChi Code
InChI=1S/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H
InChi Key
ZHSKUOZOLHMKEA-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    25 mg

    $75

    Add

    50 mg

    $134

    Add

    100 mg

    $252

    Add

    250 mg

    $589

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Bendamustine is a purine analog and DNA alkylating agent.1 It inhibits growth of SKW-3, Reh, CML-T1, BV-173, and HL-60 leukemia cell lines (IC50s = 27.0, 28.6, 15.6, 20.8, and 57.7 μM, respectively) but not MCF-7 and MDA-MB-231 breast cancer cell lines (IC50s = >200 and >200 μM, respectively).2 It kills B cell-chronic lymphocytic leukemia (B-CLL) cells derived from naïve and bendamustine-pretreated patients (LD50s = 6.8-8.3 and 3.8-4.9 mg/ml, respectively).3 Bendamustine (50 mg/kg) inhibits tumor growth by 9% and 96% alone and in combination with ofatumumab, respectively, in a JVM-3 CLL mouse xenograft model.4 It activates the DNA-damage stress response, the base excision DNA repair pathway, and apoptosis, as well as inhibits mitotic checkpoints and induces mitotic catastrophe.1 Formulations containing bendamustine have been used to treat CLL and non-Hodgkin lymphoma.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Leoni, L.M., Bailey, B., Reifert, J., et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 14(1), 309-317 (2008).

    2. Konstantinov, S.M., Kostovski, A., Topashka-Ancheva, M., et al. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J. Cancer Res. Clin. Oncol. 128(5), 271-278 (2002).

    3. Schwänen, C., Hecker, T., Hübinger, G., et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 16(10), 2096-2105 (2002).

    4. Haskova, Z., Whitacre, M.N., Dede, K.A., et al. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia. Br. J. Haematol. 156(3), 402-404 (2012).